Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum
- PMID: 11302563
- DOI: 10.1055/s-2001-15180
Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum
Abstract
Hypericum perforatum is considered an effective alternative to the synthetic antidepressants in the treatment of mild-to-moderate depression. Recently, we showed that the effects on neurotransmitter contents in different brain regions of laboratory animals are more evident after administration of hypericum extracts containing a higher concentration of flavonoids, thus suggesting that these compounds are important in the antidepressant action of hypericum perforatum. We studied the effects of Ph-50, a hypericum extract standardized to flavonoids (50%) and containing 0.3% hypericin and 4.5% hyperforin on brain serotonin content, norepinephrine and dopamine by a high-performance liquid chromatography method in discrete brain areas (cortex, diencephalon and brainstem) in male Sprague-Dawley rats. Moreover, we evaluated the effects of Ph-50 alone or in association with sulpiride (a dopamine receptor antagonist), metergoline (a serotonin receptor antagonist) and 6-hydroxydopamine (6-OH-DA, destroying norepinephrine-containing neurons) using a forced-swimming test in the rat. Hypericum extract (Ph-50; 250-500 mg/kg) with acute oral administration enhanced serotonin, norepinephrine and dopamine content in the brain and reduced the immobility time of rats in the forced-swimming test. Sulpiride, metergoline and 6-OH-DA significantly increased the period of immobility in the forced-swimming test for the rats receiving hypericum extract (Ph-50). The results indicate that the neurotransmitters studied could be involved in the anti-immobility effects of hypericum, and suggest that its antidepressant action is probably mediated by serotonergic, noradrenergic and dopaminergic system activation.
Similar articles
-
Effect of acute administration of hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system.Pharmacopsychiatry. 2000 Jan;33(1):14-8. doi: 10.1055/s-2000-8449. Pharmacopsychiatry. 2000. PMID: 10721879
-
The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake.Neuropharmacology. 2005 Dec;49(7):1042-52. doi: 10.1016/j.neuropharm.2005.06.002. Epub 2005 Jul 22. Neuropharmacology. 2005. PMID: 16040063
-
Hypericum perforatum L. (St John's wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment?Phytother Res. 2010 Feb;24(2):249-51. doi: 10.1002/ptr.2921. Phytother Res. 2010. PMID: 19585471
-
Bupropion: a review of its mechanism of antidepressant activity.J Clin Psychiatry. 1995 Sep;56(9):395-401. J Clin Psychiatry. 1995. PMID: 7665537 Review.
-
Testing the antidepressant effects of Hypericum species on animal models.Pharmacopsychiatry. 1997 Sep;30 Suppl 2:125-8. doi: 10.1055/s-2007-979532. Pharmacopsychiatry. 1997. PMID: 9342773 Review.
Cited by
-
Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance.AAPS PharmSci. 2001;3(4):E26. doi: 10.1208/ps030426. AAPS PharmSci. 2001. PMID: 12049489 Free PMC article.
-
Hypericum perforatum attenuates nicotine withdrawal signs in mice.Psychopharmacology (Berl). 2003 Sep;169(2):186-9. doi: 10.1007/s00213-003-1492-0. Epub 2003 Apr 29. Psychopharmacology (Berl). 2003. PMID: 12719964
-
Opportunities in Novel Psychotropic Drug Design from Natural Compounds.Int J Neuropsychopharmacol. 2019 Sep 1;22(9):601-607. doi: 10.1093/ijnp/pyz042. Int J Neuropsychopharmacol. 2019. PMID: 31353393 Free PMC article. Review.
-
The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.CNS Drugs. 2010 Mar;24(3):207-25. doi: 10.2165/11530120-000000000-00000. CNS Drugs. 2010. PMID: 20155996 Clinical Trial.
-
Clinically relevant safety issues associated with St. John's wort product labels.BMC Complement Altern Med. 2008 Jul 17;8:42. doi: 10.1186/1472-6882-8-42. BMC Complement Altern Med. 2008. PMID: 18637192 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical